Skip to main content

Table 3 Enrollment and outcomes in studies using Pritchard or modified Pritchard regimens

From: An integrative review of the side effects related to the use of magnesium sulfate for pre-eclampsia and eclampsia management

  Enrollment N Outcomes N (%)
Study Subjects Pre-eclampsia Eclampsia Affected patella reflex Respiratory depression Oliguria Skipped dose Calcium gluconate Maternal death
All Due to MgSO4
PRITCHARD
Alauddin 459 0 459 2 0 4 6 0 17 0
Bhattacharya 50 50 0   2 8 10   0 0
Bhattacharjee 70 0 70    0    3 0
Chowdhury 480 0 480 15 0 15 15   24 0
Chissell 9 9   0 0 0 0   0 0
Crowther 24 0 24   0 3    1 0
Ekele 19 0 19 0 0 1 1 0 0 0
Malapaka 54 16 38 19 1 19 331   1 1
Manorot 25 25 0 0 0 0 0 0 0 0
Mundle 153 153 0     122   0 0
Shoaib 50 50    0     0 0
SUBTOTALS 1393 303 1090 36 (2.6) 3 (0.2) 50 (3.6) 77 (5.5) 0 (0) 46 (3.3) 1 (0.1)
PRITCHARD MODIFIED
Bhattacharjee 67   67 0 0 0 0   1 0
Bhalla 45 0 45   0 2   0 0 0
Malapaka 72 37 35 5 0 7 125   1 0
Mahajan A 3 58 0 58 18 0 0 18 0 0  
Mahajan B 4 37 0 37 21 0 3 24 0 0  
Shoaib 50 50    0     0 0
SUBTOTALS 329 87 242 44 (13.4) 0 (0) 12 (3.7) 54 (16.4) 0 (0) 2 (0.6) 0 (0)
TOTALS 1722 390 1332 80 (4.7) 3 (0.2) 62 (3.6) 131 (7.6) 0 (0) 48 (2.8) 1 (0.1)
  1. 1 14 stopped due to signs of magnesium sulfate toxicity; 2 10 stopped treatment due to woman’s request, side effects, oliguria or renal failure, or signs of toxicity and 2 due to provider error or provider preference (Personal communication); 3Group A received 10 g loading dose; 4Group B received 6 g loading dose; 5 1 stopped due to signs of magnesium sulfate toxicity.